This comprehensive review explores the pathogenesis, imaging detection, and clinical implications of left ventricular myocardial fibrosis in atrial fibrillation and heart failure with reduced ejection fraction.
This comprehensive review highlights the clinical implications of left ventricular fibrosis in managing atrial fibrillation among patients with heart failure with reduced ejection fraction.
Atrial fibrillation (AF) and heart failure commonly coexist and their concurrent presence is linked to worse clinical outcomes. While the role of atrial fibrosis in shaping the atrial substrate and influencing post-ablation success has been described, the impact of left ventricular (LV) myocardial fibrosis remains less clearly defined. This contemporary review explores the pathogenesis of LV fibrosis, imaging modalities for its detection and the clinical implications of ventricular fibrosis for AF management in the setting of heart failure with reduced ejection fraction. We also highlight key knowledge gaps and outline priorities for future research to refine risk stratification and guide therapy.
Cho et al. (Mon,) conducted a review in Atrial fibrillation and heart failure with reduced ejection fraction. Left ventricular myocardial fibrosis was evaluated. This comprehensive review explores the pathogenesis, imaging detection, and clinical implications of left ventricular myocardial fibrosis in atrial fibrillation and heart failure with reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: